Heart Failure Incidence Among Diabetic Patients in India
Prevalence of Heart Failure in Type 2 Diabetes
In India, approximately 89.8 million individuals are affected by Type 2 Diabetes (T2D). Among these patients, the incidence of heart failure (HF) is around 50%, with a 33% increased risk of hospitalization compared to non-diabetic individuals. The challenge is compounded by the presence of undiagnosed heart failure, which adds to the overall burden on the healthcare system.
Impact of Glycemic Control on Heart Failure Risk
Poor glycemic control significantly elevates the risk of heart failure. Research indicates that each 1% increase in HbA1c levels correlates with a heightened risk of developing heart failure. This presents a clinical challenge: achieving optimal glycemic targets while avoiding medications that might adversely affect cardiac function.
Importance of Cardio-Protective Therapies
Today’s clinical decisions are increasingly influenced by the necessity for therapies that provide cardio protection. Medications such as the combination of SGLT2 inhibitors (like dapagliflozin) and DPP-4 inhibitors (like sitagliptin) in a fixed-dose combination (FDC) have emerged as critical considerations in managing T2D patients with heart failure.
Clinical Benefits of SGLT2 Inhibitors in Heart Failure
Redefined Outcomes with SGLT2 Inhibitors
SGLT2 inhibitors, particularly dapagliflozin, have shown significant advantages in treating heart failure. Dapagliflozin operates by inhibiting SGLT2, leading to reduced glucose reabsorption and promoting osmotic diuresis, which helps alleviate volume overload. Furthermore, it enhances myocardial energy metabolism through fatty acid oxidation in insulin-resistant cardiomyocytes while also minimizing myocardial fibrosis.
Clinical Evidence Supporting Dapagliflozin
In a study involving T2D patients with heart failure and reduced ejection fraction (HFrEF), dapagliflozin demonstrated impressive results. The findings included a reduction in HbA1c by 2.54% (from 8.62% to 6.08%), an improvement in HOMA-IR by 1.49 (from 4.47 to 2.98), and a notable increase in left ventricular ejection fraction (LVEF) by 39.42% (from 33.82% to 73.24%). Additionally, the treatment led to a decrease in left ventricular end-systolic diameter (LVESD) by 13.24 mm (from 44.71 mm to 31.47 mm), alongside reductions in cardiac troponin I (cTnI) by 43.5% (from 0.62 to 0.35 μg/L), CK-MB by 32.2% (from 28.35 to 19.24 U/L), and NT-proBNP by 21.1% (from 673.53 to 531.76 ng/L), all statistically significant.